Phase2 study of Glivec (imatinib mesylate, formerly known as STI571) in patients with relapsed o refractory sarcomas with c-kit or PDGFR [platelet derived growth factor receptors] expression.
Phase of Trial: Phase II
Latest Information Update: 30 May 2016
At a glance
- Drugs Imatinib (Primary)
- Indications Sarcoma
- Focus Therapeutic Use
- Acronyms CST1571BJP04
- 27 Mar 2012 Actual end date (Feb 2007) added as reported by University Hospital Medical Information Network - Japan.
- 07 Mar 2007 New trial record.